Table Graph
   

antiviral and associated therapy - versus standard of care - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.66 [0.23, 1.94]< 10%2 studies (2/-)77.3 %some concernnot evaluable moderatecrucial-
new illness compatible with Covid-19 0.06 [0.03, 0.11]< 10%1 study (1/-)100.0 %NAnot evaluable important-
infection (PCR positive symptomatic or not) 0.86 [0.52, 1.42]< 10%1 study (1/-)72.2 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.88 [0.44, 1.77]< 10%2 studies (2/-)64.4 %some concernnot evaluable moderateimportant-
adverse events 20.17 [15.61, 26.05]< 10%2 studies (2/-)0.0 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons